Trevena, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • TRV045
    • TRV250
    • TRV734
  • Products
    • OLINVYK® (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact
    • Contact Medical Information
    • Whistleblower Hotline

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
    • IRS Form 8937
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

Dec 04, 2023 7:02am EST

Trevena Awarded OLINVYK Agreement with Premier, Inc.

Dec 04, 2023 7:00am EST

Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

Nov 30, 2023 7:00am EST

Trevena Reports Third Quarter 2023 Results and Provides Business Update

Nov 14, 2023 7:00am EST

Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

Nov 09, 2023 7:00am EST

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

Oct 16, 2023 7:00am EDT

Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

Oct 02, 2023 7:00am EDT

Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

Sep 06, 2023 7:01am EDT

Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement

Sep 06, 2023 7:00am EDT

Trevena Reports Second Quarter 2023 Results and Provides Business Update

Aug 14, 2023 7:00am EDT
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...34
Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
© 2023 Trevena, Inc. All Rights Reserved.
Privacy Policy Terms of Use Disclaimer Sitemap